Background Following the emergency use authorisation of the Pfizer–BioNTech mRNA COVID-19 vaccine
BNT162b2 (international non-proprietary name tozinameran) in Israel, the Ministry of Health (MoH) launched a
campaign to immunise the 6∙5 million residents of Israel aged 16 years and older. We estimated the real-world
effectiveness of two doses of BNT162b2 against a range of SARS-CoV-2 outcomes and to evaluate the nationwide
public-health impact following the widespread introduction of the vaccine.